Nitric oxide mechanism in the protective effect of antidepressants against 3-nitropropionic acid-induced cognitive deficit, glutathione and mitochondrial alterations in animal model of Huntington's disease

Behavioural Pharmacology

Volumn 21, Issue 3, 2010, Pages 217-230

  Kumar, Puneet ^a   Kalonia, Harikesh ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3 nitropropionic acid; Antidepressants; Glutathione; Huntington's disease; Mitochondria; Nitric oxide; Rat

Indexed keywords

ARGININE; GLUTATHIONE; IMIPRAMINE; MITOCHONDRIAL ENZYME; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; HIPPOCAMPUS; HUNTINGTON CHOREA; MALE; MAZE TEST; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; COGNITION DISORDERS; CONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRON TRANSPORT COMPLEX IV; GLUTATHIONE; HIPPOCAMPUS; HUNTINGTON DISEASE; MALE; MAZE LEARNING; MITOCHONDRIA; MOTOR ACTIVITY; NADH DEHYDROGENASE; NITRIC OXIDE; NITRO COMPOUNDS; OXIDATIVE STRESS; PROPIONIC ACIDS; RATS; STATISTICS, NONPARAMETRIC; SUCCINATE DEHYDROGENASE; TIME FACTORS;

EID: 77952353432     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833a5bf4     Document Type: Article

References (67)

1. Akula KK, Dhir A, Kulkarni SK (2008). Nitric oxide signaling pathway in the anti-convulsant effect of adenosine against pentylenetetrazol-induced seizure threshold in mice. Eur J Pharmacology 587:129-134.
2. Alexi T, Hughes PE, Faull RL, Williams CE (1998). 3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. Neuroreport 9:R57-R64.
3. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, et al. (1993). Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192.
4. Berman SB, Hastings TG (1999). Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 73:1127-1137.
5. Cipriani S, Bizzoco E, Gianfriddo M, Melani A, Vannucchi MG, Pedata F (2008). Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice. Exp Neurol 213:163-170.
6. Cooke JD, Grover LM, Spangler PR (2009). Venlafaxine treatment stimulates expression of BDNF protein in frontal cortex and inhibits LTP in hippocampus. Neuroscience 162:1411-1419.
7. Cruz R, Almaguer Melian W, Bergado Rosado JA (2003). Glutathione in cognitive function and neurodegeneration. Rev Neurol 36:877-886.
8. Cruz-Aguado R, Almaguer-Melian W, Diaz CM, Lorigados L, Bergado J (2001). Behavioral and biochemical effects of glutathione depletion in the rat brain. Brain Res Bull 55:327-333.
9. De Marchi N, Daniele F, Ragone MA (2001). Fluoxetine in the treatment of Huntington's disease. Psychopharmacology (Berl) 153:264-266.
10. Deshpande SB, Hida H, Takei-Io N, Masuda T, Baba H, Nishino H (2006). Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats. Brain Res 1108:205-215.
11. Dhir A, Kulkarni SK (2007). Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog Neuropsychopharmacol Biol Psychiatry 31:921-925.
12. Dhir A, Kulkarni SK (2008). Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice. Pharmacol Biochem Behav 89:563-571.
13. Dringen R (2000). Metabolism and functions of glutathione in brain. Prog Neurobiol 62:649-671.
14. Duckworth EA, Koutouzis TK, Borlongan CV, Gordon MN, Willing AE, Cahill DW, Sanberg PR (1999). Rats receiving systemic 3-nitropropionic acid demonstrate impairment of memory in Morris water maze. Psychobiology 27:561-566.
15. Ellman GL (1959). Tissue sulfhydryl groups. Arch Biochem Biophysics 82:70-77.
16. Eren I, Naziroglu M, Demirdas A, Celik O, Uguz AC, Altunbasak A, et al. (2007). Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochem Res 32:497-505.
17. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, et al. (2001). Phenolic anti-inflammatory antioxidant reversal of Ab-induced cognitive deficits and neuropathology. Neurobiol Aging 22:993-1005.
18. Gornall AG, Bardawill CJ, David MM (1949). Determination of serum proteins by means of the biuret reaction. J Biol Chem 177:751-766.
19. Habig WH, Pabst MJ, Jakoby WS (1974). Glutathione-S-Transferase: the first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130-7139.
20. Hoth KF, Paulsen JS, Moser DJ, Tranel D, Clark LA, Bechara A (2007). Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol 29:365-376.
21. Huang LS, Sun G, Cobessi D, Wang AC, Shen JT, Tung EY, et al. (2006). 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J Biol Chem 281:5965-5972.
22. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993). Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43:2689-2695.
23. Jin Y, Lim CM, Kim SW, Park JY, Seo JS, Han PL, et al. (2009). Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 1281:108-116.
24. Karanian DA, Baude AS, Brown QB, Parsons CG, Bahr BA (2006). 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism. Hippocampus 16:834-842.
25. Keilhoff G, Becker A, Grecksch G, Bernstein HG, Wolf G (2006). Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropsychopharmacology 31:1165-1176.
26. King TE (1967). Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol 10:322-331.
27. King TE, Howard RL (1967). Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol 10:275-284.
28. Knott AB, Bossy-Wetzel E (2008). Nitric oxide in health and disease of the nervous system. Antioxid Redox Signal 11:541-554.
29. Knuuttila JE, Toronen P, Castren E (2004). Effects of antidepressant drug imipramine on gene expression in rat prefrontal cortex. Neurochem Res 29:1235-1244.
30. Kulkarni SK (2008). Practical pharmacology and clinical pharmacology. 1st ed. New Delhi, India: Vallabh Parkashan.
31. Kumar P, Kumar A (2009a). Effect of lycopene and epigallocatechin-3- gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: a novel nitric oxide mechanism. Food Chem Toxicol 47:2522-2530.
32. Kumar P, Kumar A (2009b). Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Hunting-ton's disease. J Med Food 12:591-600.
33. Kumar P, Kumar A (2009c). Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol 615:91-101.
34. Kumar P, Kumar A (2009d). Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 33:100-108.
35. Kumar P, Kumar A (2009e). Neuroprotective effect of cyclosporine and FK506 against 3-nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. Neurosci Res 63:302-314.
36. Kumar P, Padi SS, Naidu PS, Kumar A (2006). Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol 17:485-492.
37. Kumar P, Padi SS, Naidu PS, Kumar A (2007). Possible neuroprotective mechanisms of curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity. Methods Find Exp Clin Pharmacol 29:19-25. (Pubitemid 46447219)
38. Kumaran S, Subathra M, Balu M, Panneerselvam C (2004). Age-associated decreased activities of mitochondrial electron transport chain complexes in heart and skeletal muscle: role of L-carnitine. Chem Biol Interact 148:11-18.
39. Lin MT, Beal MF (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787-795.
40. Linden AM, Vaisanen J, Lakso M, Nawa H,Wong G, Castren E (2000). Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J Mol Neurosci 14:27-37.
41. Liu X, Luo X, Hu W (1992). Studies on the epidemiology and etiology of moldy sugarcane poisoning in China. Biomed Environ Sci 5:161-177.
42. Liu Y, Peterson DA, Kimura H, Schubert D (1997). Mechanisms of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide (MTT) reduction. J Neurochemistry 69:581-593.
43. Lucassen PJ, Fuchs E, Czeh B (2004). Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry 55:789-796.
44. Maher P (2005). The effects of stress and aging on glutathione metabolism. Ageing Res Rev 4:288-314.
45. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20:9104-9110.
46. Montoya A, Pelletier M, Menear M, Duplessis E, Richer F, Lepage M (2006a). Episodic memory impairment in Huntington's disease: a meta-analysis. Neuropsychologia 44:1984-1994. (Pubitemid 43927985)
47. Montoya A, Price BH, Menear M, Lepage M (2006b). Brain imaging and cognitive dysfunctions in Huntington's disease. J Psychiatry Neurosci 31:21-29.
48. Nowakowska E, Kus K, Bobkiewicz-Kozlowska T, Hertmanowska H (2002). Role of neuropeptides in antidepressant and memory improving effects of venlafaxine. Pol J Pharmacol 54:605-613.
49. Nowakowska E, Kus K, Chodera A (2003). Comparison of behavioural effects of venlafaxine and imipramine in rats. Arzneimittelforschung 53:237-242.
50. Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, et al. (1996). Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 16:3019-3025.
51. Pandey M, Varghese M, Sindhu KM, Sreetama S, Navneet AK, Mohanakumar KP, et al. (2008). Mitochondrial NAD +-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J Neurochem 104:420-434.
52. Pelegri C, Duran-Vilaregut J, del Valle J, Crespo-Biel N, Ferrer I, Pallas M, et al. (2008). Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid. Int J Dev Neurosci 26:665-671.
53. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, et al. (2008). The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol 210:154-163.
54. Ringen R, Hirrlinger J (2003). Glutathione pathways in the brain. Biol Chem 384:505-516.
55. Sameer NG, Manoj AU, Dadasaheb MK, Snehal MB, Nishikant KS (2009). Neuropeptide Y modulates the antidepressant activity of imipramine in olfactory bulbectomized rats: Involvement of NPY Y1 receptors. Brain Res 1266:45-53.
56. Schmitt JA, Kruizinga MJ, Riedel WJ (2001). Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 15:173-179.
57. Shear DA, Haik KL, Dunbar GL (2000). Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport 11:1833-1837.
58. Shoulson I (1981). Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31:1333-1335.
59. Slamon ND, Pentreath VW (2000). Antioxidant defense against antidepressants in C6 and 1321N1 cells. Chem Biol Interact 127:181-199.
60. Sottocasa GL, Kuylenstierna B, Ernster L, Bergstrand A (1967). An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol 32:415-438.
61. Sugino T, Nozaki K, Takagi Y, Hattori I, Hashimoto N, Yodoi J (1999). Expression and distribution of redox regulatory protein, thioredoxin after metabolic impairment by 3-nitropropionic acid in rat brain. Neurosci Lett 275: 145-148.
62. Verny C, Allain P, Prudean A, Malinge MC, Gohier B, Scherer C, et al. (2007). Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene. Eur J Neurol 14:1344-1350.
63. Villaran RF, Tomas-Camardiel M, de Pablos RM, Santiago M, Herrera AJ, Navarro A, et al. (2008). Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochon-drial respiratory inhibition and free radicals production. Neurotoxicology 29:244-258.
64. Xia Z, Lundgren B, Bergstrand A, DePierre JW, Nassberger L (1999). Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and citalopram and the effects on these changes by Bcl-2 and Bcl-X(L). Biochem Pharmacol 57:1199-1208.
65. Xu H, Steven Richardson J, Li XM (2003). Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 28:53-62.
66. Zafir A, Ara A, Banu N (2009). In-vivo antioxidant status: a putative target of antidepressant action. Biol Psychiatry 33:220-228.
67. Zahler WL, Cleland WW (1968). A specific and sensitive assay for disulfides. J Biol Chem 243:716-719.